Skip to content Skip to footer
Subscribe Now
VIEWPOINTS

Regeneron at ASH’24: Aafia Chaudhry in a Stimulating Dialogue Exchange with PharmaShots 

Shots:   Recently, Regeneron presented Odronextamab’s data in treating patients with different B-NHL subtypes (OLYMPIA studies) and marginal zone lymphoma (ELM-2 study)  Aafia Chaudhry, Vice President, Global Program Head for Hematology-Oncology at Regeneron, discusses Odronextamab’s ongoing studies as monotherapy and in combination to treat various malignancies  Aafia shares the upcoming PDUFA date on July 30th for…
July 2, 2025

Read more

Enhancing Hematologic Care: Lorah Perlee from Regeneron in a Riveting Dialogue Exchange with PharmaShots
VIEWPOINTS

Enhancing Hematologic Care: Lorah Perlee from Regeneron in a Riveting Dialogue Exchange with PharmaShots

Shots:  At ASH 2024, Regeneron shared data from the P-III exploratory cohort investigating the pozelimab and cemdisiran combination (poze-cemdi) in patients with paroxysmal nocturnal hemoglobinuria  The novel combination (poze-cemdi) achieved meaningful control of intravascular hemolysis compared to ravulizumab   PharmaShots welcomes Lorah Perlee, Vice President, Global Program Head, Hematology and Translational Sciences at Regeneron, for an…
June 23, 2025

Read more

NEWS

Regeneron Enters a ~$2B In-Licensing Deal with Hansoh Pharma for HS-20094, Expanding its Obesity Portfolio

Shots: Regeneron has entered into an in-licensing agreement with Hansoh for exclusive global clinical development & commercialization rights of HS-20094, excl. Mainland China, Hong Kong & Macau As per the deal, Hansoh will receive $80M upfront & ~$1.93B in development, regulatory & sales milestones, with low double digits royalties on sales in Regeneron-licensed areas HS-20094…
June 3, 2025

Read more

Regeneron & Sanofi
NEWS

Regeneron and Sanofi Report P-III (AERIFY-1 & AERIFY-2) Trials Data of Itepekimab for Chronic Obstructive Pulmonary Disease (COPD)

Shots: P-III (AERIFY-1 & AERIFY-2) trials assessed itepekimab (SC, Q2W or Q4W) vs PBO as an add-on therapy in pts (40-85yrs.) with mod. to sev. COPD, who haven’t smoked for ≥6mos.; data to be discussed with regulatory bodies  AERIFY-1 (n=1127) met its 1EP of reduced exacerbations, with Q2W (n=375) showing a 27% reduction at Wk.…
May 30, 2025

Read more

Viz.ai, Sanofi & Regeneron
NEWS

Viz.ai Enters a Multi-Year Partnership with Sanofi and Regeneron to Improve Management and Care of COPD

Shots: Viz.ai has entered into a multi-year collaboration with Sanofi & Regeneron to deploy and evaluate its AI-powered chronic obstructive pulmonary disease (COPD) workflow solution Sanofi, Regeneron, and Viz.ai collaborated on an AI-powered solution to improve care for high-risk COPD pts, focusing on how the Viz COPD module can enhance EHR workflows, access to care,…
May 21, 2025

Read more

23andMe
NEWS

Regeneron to Acquire 23andMe Assets for $256M

Shots: Regeneron has entered into an asset purchase agreement with 23andMe for $256M, strengthening Regeneron’s genetics-guided research & drug development activities Regeneron to acquire key assets of 23andMe, incl. Personal Genome Service, Total Health & Research Services business lines, plus its Biobank & associated assets, with services continuing uninterrupted; closing is expected in Q3’25 23andMe…
May 20, 2025

Read more

Regeneron & Fujifilm
NEWS

Regeneron Enters a ~$3B Multi-Year Manufacturing Agreement with FUJIFILM Diosynth Biotechnologies

Shots: FUJIFILM Diosynth Biotechnologies & Regeneron have entered into a 10-year manufacturing supply agreement, under which FUJIFILM will provide US-based manufacturing services for Regeneron As per the deal, FUJIFILM will receive ~$3B to manufacture biopharmaceuticals for Regeneron at its Holly Springs, North Carolina facility, which will begin operations in late 2025 Holly Springs site is…
April 23, 2025

Read more

Load more